Marie-Eve Beaulieu

About

Dr. Beaulieu currently leads Peptomyc’s pipeline expansion activities and coordinates the chemistry, manufacturing and controls as well as biomarker discovery activities related to Peptomyc’s lead asset, OMO-103. Marie-Eve gained extensive experience in pharmaceutical development of therapeutic proteins and peptides through her previous work with the pharmaceutical industry and the preclinical development of OMO-103. After having established from scratch Peptomyc’s Protein Platform and discovered the cell penetrating potential of Omomyc, Marie-Eve helped building the company strategy, achieve successful fundraising (public >5MEur and private ~30MEur) and reach key development milestones for OMO-103 (successful clinical trial approval by AEMPS and BfArm by leading IMPD and IB preparation).  Marie-Eve has co-authored 4 patent applications, 28 peer-reviewed publications and 4 book chapters. She awarded several competitive fellowships (CREFSIP scholarship, MITACS (postdoc fellow at Theratechnologies Inc., Montreal, Canada) and FRSQ postdoctoral award from the Quebec government. 

Work

Peptomyc S.L.

Spain

→

Vall d'Hebron Institute of Oncology

Spain

→

Education

Université de Sherbrooke Faculté de Médecine et des Science de la Santé

Canada
→
Ph.D.

Publications

The Structural Determinants of GPCR Binding and Activation: Insights from Mutagenesis and Molecular Modeling Studies of the Human Angiotensin II Type 1 (hAT1) Receptor

Understanding Biology Using Peptides

other

Photolabeling with N-Terminal Urotensin II Photoprobes Identifies Methionine 288 of Rat Urotensin Receptor as a Contact Point

Understanding Biology Using Peptides

other

Structure Determination of the Human Angiotensin II Receptor Type 1 by the Methionine Proximity Assay

Understanding Biology Using Peptides

other

Data from MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding

preprint

Supplementary Data from MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding

preprint

Supplementary Data from MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding

preprint

Data from MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding

preprint

MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding

Cancer Research Communications

journal-article

Integrated requirement of non-specific and sequence-specific DNA binding in Myc-driven transcription.

The EMBO journal

journal-article

The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets.

Life science alliance

journal-article

MYC, MYCL, and MYCN as therapeutic targets in lung cancer

Expert Opinion on Therapeutic Targets

journal-article

Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein.

Cells

journal-article

Bioactive cell penetrating peptides and proteins in cancer: a bright future ahead.

Current opinion in pharmacology

journal-article

Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy

Science Translational Medicine

journal-article

Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

journal-article

Finding MYCure

Molecular & Cellular Oncology

journal-article

BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC.

Oncotarget

journal-article

Strategies to Inhibit Myc and Their Clinical Applicability

Frontiers in Cell and Developmental Biology

journal-article

Abstract 396: Ibrutinib exerts potent antifibrotic activity in a mouse model of pancreatic adenocarcinoma

Cancer Research

journal-article

Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.

Cancer research

journal-article

Abstract PR10: Preclinical validation of Myc inhibition by a new generation of Omomyc-based cell penetrating peptides

Molecular Cancer Research

journal-article

Abstract 2645: Preclinical validation of Myc inhibition by a new generation of Omomyc-based inhibitors

Cancer Research

journal-article

Abstract B23: Pushing Myc inhibition towards the clinic by direct delivery of cell-penetrating peptides

Molecular Cancer Research

journal-article

Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis

Nature Communications

journal-article

Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis.

Nature communications

journal-article

Methods for the Expression, Purification, Preparation, and Biophysical Characterization of Constructs of the c-Myc and Max b-HLH-LZs

The Myc Gene

other

Methods for the expression, purification, preparation, and biophysical characterization of constructs of the c-Myc and Max b-HLH-LZs.

Methods in molecular biology (Clifton, N.J.)

journal-article

Solution structure of Miz-1 zinc finger 8

other

Critical hydrogen bond formation for activation of the angiotensin II type 1 receptor.

The Journal of biological chemistry

journal-article

Critical Hydrogen Bond Formation for Activation of the Angiotensin II Type 1 Receptor

Journal of Biological Chemistry

journal-article

NMR structure note: solution structure of human Miz-1 zinc fingers 8 to 10.

Journal of biomolecular NMR

journal-article

NMR structure note: solution structure of human Miz-1 zinc fingers 8 to 10

Journal of Biomolecular NMR

journal-article

New structural determinants for c-Myc specific heterodimerization with Max and development of a novel homodimeric c-Myc b-HLH-LZ.

Journal of molecular recognition : JMR

journal-article

New structural determinants for c-Myc specific heterodimerization with Max and development of a novel homodimeric c-Myc b-HLH-LZ,

Journal of Molecular Recognition

journal-article

Solution structure of Miz-1 zinc finger 10

other

Solution structure of Miz-1 zinc finger 9

other

Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor

Biochemical Pharmacology

journal-article

Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor.

Biochemical pharmacology

journal-article

Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites

Biochemical Journal

journal-article

Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.

The Biochemical journal

journal-article

Inhibition of human matriptase by eglin c variants

FEBS Letters

journal-article

Inhibition of human matriptase by eglin c variants.

FEBS letters

journal-article

Determining the environment of the ligand binding pocket of the human angiotensin II type I (hAT1) receptor using the methionine proximity assay.

The Journal of biological chemistry

journal-article

Determining the Environment of the Ligand Binding Pocket of the Human Angiotensin II Type I (hAT1) Receptor Using the Methionine Proximity Assay

Journal of Biological Chemistry

journal-article

Molecular model of a complex between [Sar1, Bpa8]AngII and hAT1 receptor

other

Constitutive activation of the angiotensin II type 1 receptor alters the spatial proximity of transmembrane 7 to the ligand-binding pocket.

The Journal of biological chemistry

journal-article

Structural determinants regulating expression of the high affinity leukotriene B4 receptor: involvement of dileucine motifs and alpha-helix VIII.

The Journal of biological chemistry

journal-article

Constitutive Activation of the Angiotensin II Type 1 Receptor Alters the Spatial Proximity of Transmembrane 7 to the Ligand-binding Pocket

Journal of Biological Chemistry

journal-article

Residues 293 and 294 are ligand contact points of the human angiotensin type 1 receptor.

Biochemistry

journal-article

Residues 293 and 294 Are Ligand Contact Points of the Human Angiotensin Type 1 Receptor†

Biochemistry

journal-article